Use of phenoxyacetic acid derivatives for treating hyperactive bladder

A drug, bladder technology, applied in the field of new indications, can solve problems such as the treatment effect of overactive bladder that has not been mentioned

Inactive Publication Date: 2009-07-29
KISSEI PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The description of the application does not mention the therapeutic effect of these substances on overactive bladder

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of phenoxyacetic acid derivatives for treating hyperactive bladder
  • Use of phenoxyacetic acid derivatives for treating hyperactive bladder
  • Use of phenoxyacetic acid derivatives for treating hyperactive bladder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The present invention relates to the use of phenoxyacetic acid derivatives as described in EP1095932 in the preparation of medicines for treating overactive bladder and pharmaceutical preparations for treating overactive bladder, the medicines or pharmaceutical preparations comprising The above-mentioned phenoxyacetic acid derivatives are used as active ingredients. According to EP1095932, the compounds forming the basis of the use and formulations according to the invention are beta-3-adrenoceptor agonists. In particular, these substances are useful in the treatment of neurogenic hyperbladder, neurogenic detrusor hyperactivity and in the treatment of congenital hyperbladder and congenital detrusor hyperactivity.

[0014] The compounds forming the basis of the applications and formulations of the present invention are represented by the following general formula I:

[0015] Chemical formula I:

[0016]

[0017] in

[0018] X is a chiral carbon atom of R or S, pref...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A formulation comprises phenoxyacetic acid derivative or its salt. A formulation comprises phenoxyacetic acid derivative of formula (I) or its salt. [Image] X and Y : chiral carbon atom; R 1OH,1-6C alkoxy, aryl-1-6C alkoxy, primary amino or mono- / di-(1-6C alkyl)amino; R 2and R 3H, halo, 1-6C alkyl, trifluoromethyl or 1-6C alkoxy; and R 4H, 1-6C alkyl, halo(1-6C alkyl), hydroxy, 1-6C alkoxy, aryl-1-6C alkoxy, 1-6C alkoxy, cyano, nitro, amino, mono- or di(1-6C alkyl)amino, carbamoyl, mono- or di(1-6C alkyl)carbamoyl or NHCOR 5; R 5H or 1-6C alkyl. Provided that at least one of R 2and R 3is H. ACTIVITY : None given. MECHANISM OF ACTION : Adrenoreceptor-beta -3 agonist. Effect of (-)-2-[4-(2-{(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino}ethyl)-2,5-dimethylphenoxyl] acetic acid (A1) on the tone of monkey detrusor was studied. The detrusor of cynomolgus monkey was isolated and dissected. Tracheal, atrial and urethral dissections were also prepared. The results were as follows: EC 50value of (A1) / isoproterenol was 8.2X10 ->7>. (A1) Exhibited lesser effect on the trachea and atria. The detrusor selectivity of (A1) was 1200 times greater (compared with the trachea) and 80 times greater (compared with the atria). (A1) Showed no effect on endothelin-1-induced tonic contraction of the isolated urethra.

Description

technical field [0001] The present invention relates to a new field of indications for phenoxyacetic acid derivatives as described in European patent application EP1095932. The compounds described in this application have now been found to be suitable for the preparation of medicaments for the treatment of overactive bladder (overactive bladder: OAB). Therefore, by utilizing these active substances, a method of treating this urinary syndrome is provided. Background technique [0002] Bladder dysfunction OAB is a prevalent chronic disease that is estimated to affect more than 50 million people in industrialized countries. [0003] According to the nomenclature published by the International Continence Association in 2002, OAB is diagnosed by symptoms. Symptoms of OAB are urgency to urinate with or without acute incontinence, usually but not necessarily accompanied by frequency and nocturia. OAB is also characterized by involuntary detrusor contractions, which can be stimul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61K31/195A61K31/192A61K31/191A61P13/10A61K31/24
CPCA61K31/24A61K31/216A61K31/192A61K31/191A61K31/195A61P13/10
Inventor 山崎芳伸小嵨正三
Owner KISSEI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap